Alignment Healthcare Stock Hit by Bearish Outlook After Costly Medicare Advantage Rating Downgrade

Alignment Healthcare Inc. (NASDAQ:ALHC) confronts potential stock pressure following the release of the Centers for Medicare & Medicaid Services’ 2027 Medicare Advantage Star Ratings. The company provides partners and patients with customized care and services. While the healthcare company secured high ratings across most of its portfolio, its most crucial California contract suffered a costly downgrade that could impact future bonus payments. The company announced that six of its seven eligible Medicare Advantage contracts earned 4 stars or higher, spanning markets in Arizona, California, Nevada, North Carolina, and Texas. Three of these plans achieved impressive 4.5-star ratings, demonstrating the provider’s ability to coordinate culturally responsive care across diverse communities. Read Also: UnitedHealth, Humana, CVS Jump As CMS Boosts Medicare Payments Costly Downgrade Despite the broader successes, the company’s largest plan, the California H3815 HMO contract, received a 3.5-star rating for 2027. Investment firm William Blair noted that this same contract previously carried a 4.0-star rating for 2026. Because the H3815 contract houses more than 75% of the company’s total health plan members, investors monitor its performance closely. Medicare Advantage contracts must maintain at least a 4-star rating to qualify for valuable bonus payments. Consequently, analyst Ryan Daniels anticipates that the rating drop could pressure the company’s shares over the coming trading sessions. Industry Concerns And Further Metrics Alignment disputes the accuracy of the 3.5-star score, arguing it ignores the contract’s longstanding success in clinical outcomes, quality measures, and member experience. “We strongly support measuring quality and holding health plans accountable for results, because seniors deserve clear and meaningful information when choosing coverage,” said Dawn Maroney, president of Alignment Health and CEO of Alignment Health Plan. “But quality measurement only works when the methodology is accurate. We believe the current Star Ratings framework has drifted too far from that goal and no longer consistently reflects quality, outcomes, and member experiences,” Maroney further said. Delving deeper into the portfolio, the company experienced a mix of contract wins and losses. The H5296 North Carolina contract dropped from a perfect 5 stars to 4.5 stars, while the H5472 Arizona contract held steady at 4.5 stars. Additionally, the H9686 Nevada contract fell from 5 stars to 4.0 stars, and a newly rated California PPO contract, H8832, debuted with 4.0 stars. “We believe the 2027 rating for our H3815 contract is inconsistent with that performance and other key indicators of quality. We intend to pursue all available administrative remedies and to litigate the measures and methodologies we believe warrant review,” Maroney added. ALHC Price Action: Alignment Healthcare shares were down 22.73% at $6.73 during premarket trading on Friday. The stock is trading at a new 52-week low, according to Benzinga Pro data. Read Also: Tesla China-Made EV Sales Rise 5% in September, Extending Growth Streak To 11 Months Despite Global Sales Slump Image via Shutterstock